CymaBay Shelves NASH Drug Seladelpar On Liver Safety Concerns

CymaBay Therapeutics Inc. already had revised the development strategy for its PPAR delta agonist seladelpar in non-alcoholic steatohepatitis (NASH) following disappointing liver fat-reduction readings from a Phase IIb study this past June, to shift to a liver enzyme endpoint. But the biotech is now shelving the drug for both NASH and primary sclerosing cholangitis (PSC), while placing on hold Phase III work with the compound in primary biliary cholangitis (PBC), based on abnormal biopsy findings.